Skip to main content
Report this ad

See also:

Biotech - The Other Silicon Valley Tech

StartOut sponsoring "Biotech – The Other Silicon Valley Tech"
StartOut sponsoring "Biotech – The Other Silicon Valley Tech"

StartOut is hosting an informative biotech event

Date: May 28, 2014

Location: Runway SF (Google Maps)

1355 Market Street San Francisco, CA, 94102

Details and registration:

Most people associate the SF Bay Area with dot com’s and computer technology companies.

But the Bay Area is also home to the biggest cluster of biotech companies in the US, over 240 companies employing more than 15,000 people.

Join us for an informative evening about the biotech industry, its growth, and the business opportunities this sector affords all of us in Silicon Valley.

According to Pricewaterhouse Coopers approximately $2.3 billion was invested in the San Francisco Bay area biotechnology and medical device companies in 2011, and biotech is growing at 15% annually. LGBT leaders are at the forefront of many of these companies.

Speakers include:


David Spellmeyer, CTO, Nodality

David is Chief Technology Officer at Nodality, a startup biotechnology company developing a proprietary technology that resolves how drugs affect patients and helps determine the right drugs to deliver to the right patients at the right times and at the right dose and schedule. Prior to Nodality, he held positions at companies both large (IBM Research, DuPont Pharmaceuticals) and small (Chiron, CombiChem, Signature BioScience).

David has been involved in over 20 corporate partnerships (non-dilutive funding), four mergers/acquisitions, formation of two joint ventures, and several rounds of venture capital funding (Series A-D) with a total deal value over $250 million. He has been involved in the development of several experimental methods and technologies (combinatorial chemistry, label-free cellular assays, and Single Cell Network Profiling), computational sciences (chemical informatics, bioinformatics, software engineering & validation, data management, data analysis), and corporate IT infrastructure (enterprise, desktop, network, collaborative tools).

David received his BS with majors in computer science and chemistry at Purdue and his Ph.D. in theoretical organic chemistry from UCLA. He completed his post-doctoral training in pharmaceutical chemistry at UCSF, where he remains an Adjunct Associate Professor. He has authored 40 scientific publications. David is a Fellow of the American Chemical Society (inducted in 2009).


Arun Apte, Founder and Chief Executive Officer, PREMIER Biosoft; Founder and Chief Executive Officer,

Arun Apte is a serial entrepreneur in the bioinformatics space. He founded and built PREMIER Biosoft, the largest independent software company providing tools for DNA analysis and mass spectrometry. He has now launched a 2nd bioninformatics company for laboratory information management systems ( and has a 3rd company in the works in the next generation sequencing space.

Arun Apte has over two decades of bioinformatics and hands on laboratory experience. He co-wrote Primer Premier and designed the core algorithmic modules of AlleleID and several other projects. He is currently responsible for galvanizing corporate financial performance, market reputation and core team performance, with a particular interest in developing new markets and forging strategic alliances with key partners. Prior to co-founding PREMIER Biosoft, he gained extensive laboratory experience at Clontech Laboratories, California. Arun Apte holds a B.A. in molecular and cell biology and biophysics from the University of California at Berkeley. He has received numerous honors and awards including the T. J. Watson scholarship from IBM, the University of California Alumni scholarship and The Regents of California scholarship. He has been published extensively on bioinformatics.

Paul J. Hastings, Chairman and Chief Executive Officer, OncoMed Pharmaceuticals

Mr. Hastings is the Chairman and CEO of OncoMed Pharmaceuticals. Prior to joining OncoMed in 2006, Mr. Hastings was President and Chief Executive Officer of QLT, Inc. Previous to that, Mr. Hastings served as President and Chief Executive Officer of Axys Pharmaceuticals, which was acquired by Celera Corporation in 2001. From 1999 to 2001, Mr. Hastings served as the President of Chiron BioPharmaceuticals, a division of Chiron Corporation. Prior to that, he was President and Chief Executive Officer of LXR Biotechnology. Mr. Hastings also held a series of management positions of increasing responsibility at Genzyme Corporation, including serving as President of Genzyme Therapeutics Europe as well as President, Genzyme Therapeutics Worldwide. Mr. Hastings also served as Vice President, Marketing and Sales and General Manager, Europe for Synergen, Inc., and previously held a series of marketing and sales management positions with Hoffmann-La Roche.

Mr. Hastings was recently Chairman of the Board of Proteolix (sold to Onyx Pharmaceuticals in 2010), and served on the boards of ViaCell (sold to Perkin-Elmer in 2007). He is currently Lead Director of Pacira Pharmaceuticals and on the board of Relypsa. He also serves as Chairman of the Emerging Companies Section of the Biotechnology Industry Organization, and serves on the board of the Bay Area Biosciences Association (BayBio) and the California Healthcare Institute (CHI).

Mr. Hastings received a Bachelor of Science degree in pharmacy from the University of Rhode Island.

Lance Berman, Chief Medical Officer and Senior Vice President, Relypsa, Inc

Lance joined Relypsa in December 2011 as Senior Vice President, Commercial Strategy and Medical Affairs and was promoted in October 2012 to Senior Vice President and Chief Medical Officer. Most recently, he was Chief Medical Officer of CPEX Pharmaceuticals where he was responsible for the clinical development of the Company’s late stage clinical product as well as its in-licensing and acquisition strategies. Prior to that, he served in various medical leadership roles at Pfizer Inc. from June 2003 to January 2009, where he was responsible for atherosclerosis, hypertension and endocrinology products serving at various times as US or Global Medical Team Leader. Previously, Lance held roles of increasing responsibility at Schering-Plough Corporation (merged with Merck) and Janssen Pharmaceuticals, Inc. (Johnson & Johnson). Lance received his Bachelor of Medicine and Bachelor of Surgery at the University of Cape Town in Cape Town, South Africa, and holds a Masters Degree in Pharmaceutical Medicine.

Jeremy Joseph, GE Ventures Healthcare Division

GE Ventures is the General Electric Company’s $1BN venture capital arm based in Menlo Park, CA and invests in healthcare, energy, software and advanced manufacturing. Prior to joining GE Ventures, Jeremy was an associate on Credit Suisse’s Pharmaceuticals & Life Sciences Tools team where he spearheaded stock investment analyses for large cap companies that include Thermo Fisher, Forest Labs and Abbvie. His professional experience spans from healthcare investment banking to equity research at firms Credit Suisse, Lazard and Morgan Stanley. Jeremy holds a B.S. in bioengineering from Rice University and a M.S. in bioengineering from University of Washington, Seattle.

Carol Nast, President, Enterprise Catalyst Group, Inc


When: Wednesday, May 28th, 2014 at 6pm – 8pm

Where: Runway | 1355 Market St., San Francisco, CA

Report this ad